Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines

Dobañoa, Carlota, Rogersa, William O., Gowdaa , Kalpana and Doolana, Denise L. (2007) Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines. Immunology Letters, 111 2: 92-102. doi:10.1016/j.imlet.2007.05.007


Author Dobañoa, Carlota
Rogersa, William O.
Gowdaa , Kalpana
Doolana, Denise L.
Title Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines
Journal name Immunology Letters   Check publisher's open access policy
ISSN 0165-2478
1879-0542
Publication date 2007-08-15
Sub-type Article (original research)
DOI 10.1016/j.imlet.2007.05.007
Volume 111
Issue 2
Start page 92
End page 102
Total pages 11
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Language eng
Subject 110704 Cellular Immunology
Formatted abstract
An effective malaria vaccine which protects against all stages of Plasmodium infection may need to elicit robust CD8+ and CD4+ T cell and antibody responses. To achieve this, we have investigated strategies designed to improve the immunogenicity of DNA vaccines encoding the Plasmodium yoelii pre-erythrocytic stage antigens PyCSP and PyHEP17, by targeting the encoded proteins to the MHC Classes I and II processing and presentation pathways. For enhancement of CD8+ T cell responses, we targeted the antigens for degradation by the ubiquitin (Ub)/proteosome pathway following the N-terminal rule. We constructed plasmids containing PyCSP or PyHEP17 genes fused to the Ub gene: plasmids where the N-terminal antigen residues were mutated from the stabilizing amino acid methionine to destabilizing arginine, plasmids where the C-terminal residues of Ub were mutated from glycine to alanine, and plasmids in which the potential hydrophobic leader sequences of the antigens were deleted. For enhancement of CD4+ T cell and antibody responses, we targeted the antigens for degradation by the endosomal/lysosomal pathway by linking the antigen to the lysosome-associated membrane protein (LAMP). We found that immunization with DNA vaccine encoding PyHEP17 fused to Ub and bearing arginine induced higher IFN-γ, cytotoxic and proliferative T cell responses than unmodified vaccines. However, no effect was seen for PyCSP using the same targeting strategies. Regarding Class II antigen targeting, fusion to LAMP did not enhance antibody responses to either PyHEP17 or PyCSP, and resulted in a marginal increase in lymphoproliferative CD4+ T cell responses. Our data highlight the antigen dependence of immune enhancement strategies that target antigen to the MHC Class I and II pathways for vaccine development.
Keyword Plasmodium yoelii
Malaria
DNA vaccines
PyHEP17
PyCSP
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 21 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 21 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 03 Mar 2009, 12:14:53 EST by Ms Lynette Adams on behalf of School of Medicine